Foundation says surfers are helping to fight CF

20 July 2008

A new US campaign has been set up by the Cystic Fibrosis Foundation, to raise awareness of a treatment for the condition discovered by accident in tests on surfers.

Several years ago, doctors in Australia noticed young surfers with cystic fibrosis had significantly healthier lungs. The doctors determined that inhaling saltwater mist has a powerful effect on rehydrating the lining of the lungs and allowing CF patients to more easily eliminate bacteria-contaminated mucus. This discovery led to the development of a hypertonic saline solution, which CF patients around the world now inhale every day. In essence, CF patients now mimic a "surf session" on a daily basis.

The recent saltwater breakthrough treatment has led the Cystic Fibrosis Foundation to form the Pipeline To A Cure campaign to raise funds and to bring about global awareness of what it describes as a unique bond between surfing and those with CF.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight